


Screening saves lives: the value of medical technologies for cardiovascular disease screening

Helping the EU reach its goal of cutting cardiovascular disease mortality by **25% by 2035**



CVD is the leading cause of mortality and disability in the European Union

60 million

Today, some 60 million Europeans are living with CVD, **with the prevalence expected to rise by 90% by 2050**

35,6 million

The global burden of CVD is projected to rise, with deaths increasing from **20,5 million in 2025 to 35,6 million by 2050.**

€282 billion

Annual cost of CVD in Europe

About the MedTech Europe Cardiovascular Sector Group

The MedTech Europe Cardiovascular Sector Group represents the Cardiovascular Medical Technology Industry, which provides solutions to the burden of CVD. Medical technologies play a central role in the fight against CVD spanning the full spectrum of patient care from diagnosis to cure, saving lives and adding tremendous value to European society.

High quality medical technologies are critical **through the entire patient pathway**. From screening, to early detection, treatment and monitoring of CVD, they improve clinical, procedural and patient outcomes, while reducing associated costs and recurrence.

PREVENTION
Risk stratification

EARLY DIAGNOSIS
AI-enabled screening

TREATMENT
Minimally invasive

MONITORING
Connected devices

REHABILITATION
Remote consultation

Our call to EU policymakers

Under the Safe Hearts Plan, adopt an EU cardiovascular health check protocol that formally recognises digital and AI-driven screening solutions and establishes standardised referral pathways connecting detection to timely and evidence-based care across Member States.

To achieve the EU goal of reducing CVD mortality by 25% by 2035, the EU Safe Hearts Plan's flagship initiative on an EU protocol on health checks for cardiovascular diseases should recognise the value of technologies and digital/AI solutions in cardiovascular disease screening.

BLOOD PRESSURE MONITOR

Higher arm device or wearable

Healthcare Setting Primary care

Disease CVD

Headline outcome

Every 10 mmHg reduction in systolic BP cuts major cardiovascular event risk by 20%, stroke by 27%, and heart failure by 28%



NT-PROBNP BLOOD TEST

Healthcare Setting Primary Care

Disease Heart Failure

Headline outcome

Reduces unnecessary specialist referrals by 40% and enables ~2x faster diagnosis



ELECTROCARDIOGRAM (ECG)

Healthcare Setting Home, Primary care, Hospital

Disease Atrial Fibrillation (AF) and others

Headline outcome

Delivers 77 life-years gained and €1,77 million in savings per 1,000 people screened



TRANSTHORACIC ECHOCARDIOGRAPHY

Healthcare Setting Hospital

Disease Aortic Stenosis (AS)

Headline outcome

130,000 undetected AS cases projected identified (UK)



AI-ENABLED STETHOSCOPE

Traditional & digital cardiac auscultation

Healthcare Setting Primary care

Disease CVD

Headline outcome

Detects valvular disease at twice the rate of a traditional stethoscope (92.3% vs 46.2% sensitivity)



POC ANALYZERS

Portable point-of-care (POC) analyzers for rapid on-site testing and automated biochemistry analyzers for full lipid profile

Healthcare Setting Primary care

Disease CVD

Headline outcome

POC lipid testing in community pharmacies identified elevated CVD risk in 51% of screened adults, of which the majority previously undiagnosed



ANKLE-BRACHIAL INDEX (ABI) SYSTEMS

Doppler Ultrasound (for peripheral pulse evaluation)

Healthcare Setting Primary care

Disease Peripheral Artery Disease (PAD)

Headline outcome

Cuts amputations by 35%, with projected EU savings of €450 million



COMPUTED TOMOGRAPHY (CT) SCANNER

For Coronary Artery Calcium (CAC)

Healthcare Setting Hospital

Disease Coronary Artery Disease (CAD), Vascular disease (aortic pathologies)

Headline outcome

Over 50% of heart attacks occur in patients classified as "low risk", while CAC scoring detects hidden disease in asymptomatic individuals, catching what standard assessment misses